Voltage prior to the first hearing: Bayer goes against US-glyphosate-judgment in appeal

Numerous U.S. lawsuits because of alleged cancer risk of the weed killers with the active ingredient glyphosate have brought the Bayer into a serious crisis. The Leverkusen-based agricultural chemical and pharmaceutical giant, has rejected the allegations, however, and has appealed the previous rulings.

The dispute, with the debacle for the group began, is now in the next round: The first hearing before the court of appeal will take place today, Tuesday (18:00 CEST) in San Francisco. Bayer wants to leave in the first glyphosate-procedure in the United States suffered a guilty verdict there cancel. However, even if this should succeed – there are a number of other US actions.

10. August 2018 for the German Dax-companies is a Raven black day: The sworn jury of a court in San Francisco ruled that the must recently, pay to the Bayer group at the end of the US seed producer Monsanto, the cancer victim, Dewayne Johnson a total of $ 289 million (260 million euros) in damages. Bayer suddenly stood with his back to the wall, even if the court reduced the amount quickly to 78 million dollars. The judgment revealed abruptly, the high risks, the group charged with the already controversial Monsanto Takeover.

Plaintiff Johnson, in the 2014 cancer of the lymph nodes was diagnosed, had made Monsanto’s weed killer Roundup to be deadly to Suffer responsible and the now Bayer belonging to companies accused of the dangers concealed. The Jury, followed, after a four-week process is largely the argument of the plaintiff side. For Bayer, it was a huge mess, the Leverkusen had bought Monsanto a short time before only for approximately 63 billion dollars – and thus the law applied loads. The rose is now growing rapidly, because the harsh judgment is called for much more the plaintiff to the Plan.

It is two more defeats before the US courts, image problems, and a more violent collapse of the Bayer share, for the Executive management to the chief Executive officer Werner Baumann was massively in the criticism. Most recently, Bayer was presented with 52.500 the Wake of the U.S. lawsuits because of alleged cancer dangers of glyphosate weed killer from Monsanto faced. The group is unaware of any wrongdoing, and the products are used properly, harmless, asserts the group again and again. The company is based on various scientific studies and regulatory authorities.

According to Bayer, the first instance guilty verdicts came about in the United States, in spite of defective evidence. In addition, had been made in the process, various errors, for example, by certain evidence were not admitted. Bayer is also likely to have not helped that in the processes so far with the laity, occupied Geschworenenjurys pronounced, the more open to the arguments of the plaintiffs ‘ lawyers, possibly as a professional judge. On appeal, this will not be the case here, a three-judge existing Panel decides.

Although Bayer’s major crisis, the first judgment went off, which is now being negotiated in appeal, could be the output in the overall analysis at the end slightly to the side note. As with the lawyers of most of the remaining plaintiffs in the United States talks about a comparison run for a long time. Experts expect a compromise, the Bayer estimated it could cost around ten billion dollars. The group stressed, however, that any such solution can only be considered “if this is economically structured in a reasonable way, that future disputes will be brought to a conclusion”.